Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
Information source: National Institute of Cancerología
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Locally Advanced Breast Cancer
Intervention: Hydralazine and magnesium valproate administration (Drug); Core-needle biopsy of the breast (Procedure)
Phase: Phase 2
Status: Terminated
Sponsored by: National Institute of Cancerología Official(s) and/or principal investigator(s):
Claudia Arce, MD, Principal Investigator, Affiliation: Division of Clinical Research, IInstituto Nacional de Cancerologia, Mexico
Summary
Aberrant DNA methylation and histone deacetylation participate in cancer development and
progression, as epigenetic alterations are common to breast cancer, in this phase II study,
the demethylating hydralazine plus the HDAC inhibitor magnesium valproate will be added to
neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess
their safety and biological efficacy.
Clinical Details
Official title: A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Primary outcome: Global DNA methylationHistone Deacetylase Activity Global gene expression
Secondary outcome: Pathological responseHydralazine plasma levels Valproic acid plasma levels
Detailed description:
Eligible patients after signing the informed consent and will undergo study evaluation and
then typed for acetylator phenotype before being treated with hydralazine at 182 mg for
rapid-, or 83 mg for slow-acetylators, and magnesium valproate at 30 mg/kg, starting from day
–7 until chemotherapy ends. Chemotherapy will consists in a regimen of four cycles of
doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days, followed by surgery to
assess the pathological response. Adjuvant radiation and additional treatment will be done in
off-protocol basis according to standard institutional policies. Blood samples and
core-needle biopsies will be taken from primary breast tumors at diagnosis and at day 8 of
treatment with hydralazine and valproate. Global cytosine content (global DNA methylation)
and histone deacetylase activity will be assessed in peripheral blood DNA. The
transcriptional profile in the primary breast tumor before and after treatment will also be
analyzed as well as the plasma levels of hydralazine and valproic acid.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
Aged 18 and older; histologically proven invasive T2-3, N0-2, and M0 (stages IIB–IIIA)
breast carcinoma; Eastern Cooperative Oncology Group performance status ≤2. Hematological
function: Absolute leukocyte count ≥4,000/mm3, platelets ≥100,000/mm3, hemoglobin ≥9. 0
g/dL. Hepatic function: total bilirubin, aspartate amino transferase and alanine amino
transferase <1. 5 the upper normal limit. Renal function: creatinine ≤1. 2 mg/dL or a
calculated creatinine clearance of ≥60 mL/min. Written informed consent.
Exclusion Criteria:
A history of allergy to sulphas, hydralazine, or magnesium valproate. Past or present
condition of rheumatic disease, central nervous system disease, heart failure from aortic
stenosis and postural hypotension as diagnosed by a physician. Previous use of the
experimental drugs. Pregnancy and breast-feeding. Uncontrolled systemic disease or
infection.
Locations and Contacts
Instituto Nacional De Cancerologia, MEXICO CITY, TLALPAN 14080, Mexico
Additional Information
Starting date: June 2005
Ending date: August 2006
Last updated: November 1, 2006
|
